Objective:

To highlight significant achievements in drug development, particularly the approval of new therapies and advancements in small molecules and biologics.

Approach:

• Professional Highlights: Approval of lisaftoclax in China for chronic lymphocytic leukemia and small lymphocytic lymphoma; significant progress in the pipeline including investigational new drug clearance for a BTK protein degrader.
• Small Molecules vs. New Modalities: Small molecules retain advantages such as oral bioavailability and ability to cross the blood-brain barrier, while evolving with new technologies like protein degraders.
• Advancements in Drug Development: Targeted protein degradation technology is rapidly advancing, with multiple candidates in clinical trials showing significant clinical benefits.
• Future of Drug Development: The distinction between small molecules and biologics will blur, with therapeutic choices driven by biology rather than historical conventions.

Key Findings:

• Lisaftoclax is the second Bcl-2 inhibitor approved globally since 2016.
• Small molecules offer unique advantages, including oral administration and crossing the blood-brain barrier.
• Targeted protein degradation is advancing quickly, with multiple candidates in clinical trials.
• Future drug development will focus on biology rather than modality.

Limitations:

• The article does not provide specific data on patient outcomes or comparative efficacy of the new therapies.

Conclusion:

The landscape of drug development is evolving, with small molecules continuing to play a crucial role alongside emerging technologies.